Finance

Lists
Q2 2026 earnings • released • EPS beat +25.60% • Revenue miss -1.17%
See results
LYB:NYSE
Lyondellbasell Industries N.v
$62.08
+2.71%
(+1.64) 1D
$63.00
+1.48% (+0.92)
Pre-market
Closed: Jul 31, 4:02:51 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LYB...
Open
$61.27
High
$62.76
Low
$60.05
Mkt. cap
20.04B
Avg. vol.
5.24M
Volume
23.05K
Dividend
4.45%
Quarterly dividend
$0.69
Ex-dividend date
Jun 1, 2026
52-wk high
$83.94
52-wk low
$41.58
EPS
-$2.49
Beta
0.28
Shares outstanding
322.78M
No. of employees
19K
Open
$61.27
High
$62.76
Low
$60.05
Mkt. cap
20.04B
Avg. vol.
5.24M
Volume
23.05K
Dividend
4.45%
Quarterly dividend
$0.69
Ex-dividend date
Jun 1, 2026
52-wk high
$83.94
52-wk low
$41.58
EPS
-$2.49
Beta
0.28
Shares outstanding
322.78M
No. of employees
19K
News stories
From sources across the web
Profile
LyondellBasell Industries N.V. is an American multinational chemical company, incorporated in the Netherlands with U.S. operations headquartered in Houston, Texas and offices in London, UK. The company is the largest licensor of polyethylene and polypropylene technologies. It also produces ethylene, propylene, polyolefins, and oxyfuels. LyondellBasell was formed in December 2007 by the acquisition of Lyondell Chemical Company by Basell Polyolefins for $12.7 billion. As of 2016, Lyondell was the third largest independent chemical manufacturer in the United States. LyondellBasell's global headquarters is located in Williams Tower in Houston, Texas. Wikipedia
About Lyondellbasell Industries N.v
CEOPeter Vanacker
Employees19K
FoundedDec 2007
HeadquartersRotterdam, South Holland, Netherlands
SectorCommodity chemical
Websitelyondellbasell.com
Analyst ratings
Based on 14 analysts giving stock ratings to LYB in the past 3 months
Buy
Buy
6
Hold
6
Sell
2
12-month forecast
Based on 14 Wall Street analysts offering 12 month price targets for LYB in the last 3 months.
Highest
Current $62.08
$83.00 (+33.70%)
Average
$68.92 (+11.02%)
Lowest
$48.00 (-22.68%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jeffrey Zekauskas
J.P. Morgan
Buy
Upgraded
$80.00
+28.9%
08/03/2026
Vincent Andrews
Morgan Stanley
Buy
Maintained
$72.00
+16%
07/20/2026
Duffy Fischer
Goldman Sachs
Sell
Maintained
$62.00
-0.1%
07/16/2026
Patrick Cunningham
Citi
Buy
Maintained
$67.00
+7.9%
07/14/2026
John McNulty
BMO Capital
Hold
Maintained
$64.00
+3.1%
07/06/2026
Michael Sison
Wells Fargo
Buy
Reiterated
$70.00
+12.8%
07/02/2026
Abigail Eberts
Wells Fargo
Buy
Reiterated
$70.00
+12.8%
07/02/2026
Hassan Ahmed
Alembic Global
Buy
Reiterated
$83.00
+33.7%
07/02/2026
John Roberts CFA
Mizuho Securities
Hold
Maintained
$62.00
-0.1%
07/01/2026
Matthew DeYoe
Bank of America Securities
Sell
Maintained
$48.00
-22.7%
06/30/2026
Arun Viswanathan
RBC Capital
Buy
Maintained
$65.00
+4.7%
06/30/2026
Joshua Spector
UBS
Hold
Reiterated
$73.00
+17.6%
06/08/2026
Unknown Analyst
Argus Research
Hold
Maintained
-
-
05/18/2026
David Begleiter
Deutsche Bank
Hold
Reiterated
$80.00
+28.9%
05/05/2026
Eric Boyes
Evercore ISI
Hold
Maintained
$70.00
+12.8%
05/04/2026
Laurence Alexander
Jefferies
Hold
Maintained
$70.00
+12.8%
03/10/2026
Frank Mitsch
Fermium Research
Buy
Upgraded
$74.00
+19.2%
03/09/2026
Kevin McCarthy
Vertical Research
Buy
Upgraded
$75.00
+20.8%
03/09/2026
Aleksey Yefremov
KeyBanc
Buy
Upgraded
$73.00
+17.6%
03/04/2026
Last report
Jul 31, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$4.30 / $3.42
+25.60%beat
Revenue / Est. (USD)
9.18B / 9.29B
-1.17%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
7.73B
7.09B
7.20B
9.18B
Cost of goods sold
6.82B
6.75B
6.50B
-
Cost of revenue
6.82B
6.75B
6.50B
-
Research and development expenses
34.00M
33.00M
36.00M
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
405.00M
376.00M
415.00M
-
Operating expense
439.00M
409.00M
451.00M
-
Total operating expenses
7.26B
7.16B
6.95B
-
Operating income
467.00M
-65.00M
250.00M
-
Other non operating income
4.00M
-21.00M
10.00M
-
EBT including unusual items
-858.00M
-144.00M
135.00M
-
EBT excluding unusual items
350.00M
-118.00M
150.00M
-
Income tax expense
-27.00M
-8.00M
-2.00M
-
Effective tax rate
3.15%
5.56%
-1.48%
-
Other operating expenses
-
-
-
-
Net income
-892.00M
-142.00M
123.00M
-
Net profit margin
-11.54%
-2.00%
1.71%
6.08%
Earnings per share
1.01
-0.26
0.49
4.30
Interest and investment income
21.00M
25.00M
31.00M
-
Interest expense
-132.00M
-134.00M
-140.00M
-
Net interest expenses
-111.00M
-109.00M
-109.00M
-
Depreciation and amortization charges
-
-
-
-
EBITDA
817.00M
167.00M
592.00M
-
Gain or loss from assets sale
6.00M
-112.00M
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps